Please assess the completion status of the following clinical trial:

Trial Title: Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* neonates born at gestational age of 35 weeks or greater~* neonates aged 0 to 14 days~* prenatally exposed to opioids~* severe NAS defined as 2 consecutive modified Finnegan Scores (MFS) \> or = 9~Exclusion Criteria:~* \< 35 weeks gestational age~* Intrauterine growth retardation defined as \<5%tile of gestational age~* postnatal treatment with barbiturates or benzodiazepines,~* major congenital anomalies~* major concomitant medical illness requiring oxygen therapy, intravenous fluids or medications.~* breastfed infants

- Gender: ALL
- Minimum Age: None
- Maximum Age: 14 Days
- Healthy Volunteers: f

Study Arms:
- Clonidine treatment (Type: EXPERIMENTAL): Infants intrauterine exposed to opioids (heroin or methadone) that demonstrate signs and symptoms of withdrawal with withdrawal scores (modified Finnegan score) greater than 9 on to consecutive scores taken 4 hours apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).